Royal Bank Of Canada Cuts Insmed (NASDAQ:INSM) Price Target to $205.00

Key Points

• Royal Bank of Canada trimmed its price target on Insmed from $220 to $205 but kept an "outperform" rating, implying roughly a 106% upside from the recent share price; analysts' consensus remains constructive with an average target near $212.
• Shares fell about 5.3% to $99.41 after Q1 results that beat estimates (EPS -$0.76 vs. -$0.90; revenue $306M), as investors focused on higher operating expenses and guidance uncertainty; insiders have also been net sellers recently.

Insmed (NASDAQ:INSM - Get Free Report) had its target price decreased by research analysts at Royal Bank Of Canada from $220.00 to $205.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has an "outperform" rating on the biopharmaceutical company's stock. Royal Bank Of Canada's price objective would suggest a potential upside of 106.22% from the company's previous close.

Other research analysts also recently issued research reports about the stock. Morgan Stanley upgraded shares of Insmed from an "equal weight" rating to an "overweight" rating and boosted their target price for the company from $166.00 to $212.00 in a research report on Monday, March 30th. Raymond James Financial started coverage on shares of Insmed in a research report on Friday, April 10th. They set an "outperform" rating and a $200.00 target price on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Insmed in a research note on Tuesday, April 21st. HC Wainwright restated a "buy" rating on shares of Insmed in a research note on Friday. Finally, Stifel Nicolaus boosted their price target on shares of Insmed from $205.00 to $208.00 and gave the company a "buy" rating in a research note on Tuesday, March 24th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Insmed has an average rating of "Buy" and a consensus price target of $211.86.

Insmed Stock Down 5.3%

Shares of Insmed stock traded down $5.59 during trading on Friday, reaching $99.41. 4,460,999 shares of the company traded hands, compared to its average volume of 2,488,815. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.83 and a quick ratio of 3.54. Insmed has a 1-year low of $64.85 and a 1-year high of $212.75. The company has a 50 day moving average price of $145.87 and a 200-day moving average price of $165.46. The firm has a market capitalization of $21.46 billion, a PE ratio of -15.52 and a beta of 0.89.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.90) by $0.14. Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The company had revenue of $305.96 million for the quarter, compared to the consensus estimate of $300.81 million. During the same quarter in the previous year, the company earned ($1.42) EPS. Insmed's quarterly revenue was up 229.7% compared to the same quarter last year. As a group, equities research analysts expect that Insmed will post -2.41 earnings per share for the current fiscal year.

Insider Buying and Selling at Insmed

In other news, insider Michael Alexander Smith sold 19,638 shares of the company's stock in a transaction on Monday, March 30th. The shares were sold at an average price of $150.98, for a total value of $2,964,945.24. Following the completion of the sale, the insider owned 51,871 shares in the company, valued at $7,831,483.58. This represents a 27.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Roger Adsett sold 88,060 shares of the company's stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the completion of the sale, the chief operating officer owned 106,810 shares of the company's stock, valued at approximately $17,584,130.30. The trade was a 45.19% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 174,589 shares of company stock worth $27,441,807. 2.10% of the stock is owned by corporate insiders.

Institutional Trading of Insmed

Institutional investors have recently made changes to their positions in the company. EULAV Asset Management bought a new stake in shares of Insmed in the 3rd quarter worth $12,961,000. Artisan Partners Limited Partnership grew its stake in shares of Insmed by 49.0% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company's stock worth $711,076,000 after acquiring an additional 1,623,342 shares in the last quarter. Atika Capital Management LLC purchased a new position in shares of Insmed in the 3rd quarter worth about $13,681,000. Nisa Investment Advisors LLC boosted its holdings in shares of Insmed by 374.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 10,466 shares of the biopharmaceutical company's stock worth $1,507,000 after buying an additional 8,261 shares during the last quarter. Finally, Nordea Investment Management AB purchased a new position in shares of Insmed in the 4th quarter worth about $3,492,000.

Insmed News Summary

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: BRINSUPRI and product/clinical progress support long‑term growth: Q1 BRINSUPRI revenue was $207.9M (sequential growth) and ARIKAYCE sales were $98.1M; Insmed reiterated BRINSUPRI 2026 revenue guidance of at least $1B and reported positive Phase 3b ENCORE results and initiation of the Phase 3 PALM‑PAH study — supports the company’s multi‑product growth story. Press Release
• Positive Sentiment: Analyst stance still constructive despite haircut: Wells Fargo trimmed its price target from $177 to $160 but kept an “overweight” rating, indicating continued analyst confidence in upside over the medium term. Coverage Note
• Neutral Sentiment: Q1 reported metrics — mixed reads: Company reported ($0.76) EPS (better than some estimates) and ~ $306M revenue (large year‑over‑year growth), and provided slides and an earnings call transcript for further detail; investors are parsing the back‑half cadence and cost trajectory. Slide Deck / Press Release Earnings Call Transcript
• Neutral Sentiment: Marketing/awareness push could expand diagnosis and uptake over time: Insmed launched a Bronchiectasis awareness campaign with Ty Pennington to drive diagnosis and BRINSUPRI awareness — a longer‑term demand catalyst rather than an immediate revenue driver. PR
• Negative Sentiment: Market reacted to perceived sales/guidance weakness and higher expenses: Headlines emphasized a revenue “miss” versus some expectations and higher Q1 operating costs; coverage and media framed these as reasons for a sharp sell‑off despite the EPS beat. That negative sentiment pressured the stock today. Zacks: Q1 Earnings/Stock Reaction
• Negative Sentiment: Higher expenses highlighted by reporters and analysts: Coverage noted elevated 1Q R&D and SG&A spending that widened losses and increased near‑term profit uncertainty, a key reason cited for the sell‑off. MarketWatch

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.